AI-Powered Drug Discovery Services

Actionable insights for every stage of your drug development program.

Ready to find answers for your program?

Solutions for Each Step of Your Pipeline

At Delta4, we empower pharma and biotech companies throughout their entire drug development journey – from early target discovery and disease- or drug-centric repositioning to side effect prediction, biomarker identification, and clinical trial design.

How It Works

Every Project Starts With A Question. Here's What Happens Next.

Share Your Challenge

Tell us about your compound, target, or research question. There's no standard brief; we work from where you are.

See the Platform in Action

We'll schedule an intro call and walk you through Hyper-C's capabilities in the context of your specific question.

Receive Your Project Proposal

We'll follow up with a tailored three-part proposal outlining scope, approach, and next steps.

Most projects begin with a single conversation.

At 4P-Pharma, our foundation is based on scientific rationale. Delta4 has provided us with this essential foundation for our co-development project, enabling us to start from the mechanism of action in the disease. This approach allows us to more accurately and quickly identify and validate therapeutic targets, making our drug development process more efficient and focused.

The Delta4 team members are highly competent in big data network analyses both from the disease side and from the drug product and pharmacology side. Their methodology of marrying one with the other led us to new intellectual property.

Thanks to DELTA4, we have been able to speed up the selection of preclinical models, that will allow us to effectively prove the beneficial effects of those drug candidates.

Their reporting is thorough and to the point. We highly recommend Delta4 as an AI partner for drug discovery and development.

Trusted By

Frequently Asked Questions

Everything you need to know about working with Delta4.

What is the typical runtime of a service project?

A typical project focused on a single use case – such as drug repositioning (indication expansion), biomarker discovery, or target identification – takes about 4-6 months. Longer collaborations or framework agreements can be established to cover multiple use cases within specific therapeutic areas.

Does Delta4 focus on specific therapeutic areas?

The Hyper-C platform supports all therapeutic areas, enabling us to offer drug discovery services for any human disease. Our current development programs focus on cardiometabolic, renal, oncologic, central nervous system, and gastrointestinal disorders.

Learn more about diseases/phenotypes covered in Hyper-C at https://delta4.ai/hyper-c/ and learn more about Delta4’s development programs at https://delta4.ai/development-programs/.

Who owns the results and generated insights?

You retain full ownership of all results related to your assets. We operate as a partner, not a competitor, and ensure that all generated insights can be directly used in your internal programs, publications, or regulatory activities.

Already on Scientist.com?

Request a Delta4 project directly through the platform

As featured on Scientist.com: Delta4’s Hyper-C platform uncovers new drug indications for Iguratimod.